Fort Washington, Pennsylvania, U.S., September 8, 2026
New clinical evidence presented at PAINWeek 2026 highlights the potential of a fixed-dose combination of TYLENOL® (acetaminophen) and naproxen for providing rapid and sustained pain relief following surgery. The data, presented by Kenvue, evaluated the combination in two randomized, double-blind, placebo-controlled clinical studies involving patients experiencing moderate-to-severe acute pain after surgical procedures. Findings from the studies showed that the combination provided greater pain relief than placebo and individual treatment components, while maintaining an analgesic effect over an extended period. The results add to the clinical evidence supporting the use of combined non-opioid analgesic approaches for acute post-surgical pain management.
Combination Therapy Delivers Rapid Pain Relief
The clinical findings presented at PAINWeek 2026 included data from studies evaluating the effectiveness of acetaminophen and naproxen administered together following surgery. The combination uses two established analgesic mechanisms: acetaminophen acts through central pain-relief pathways, while naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that reduces prostaglandin production and inflammation through cyclooxygenase inhibition. According to the reported findings, patients receiving the acetaminophen and naproxen combination experienced significantly greater pain relief compared with placebo and the individual active ingredients in the evaluated surgical pain models. The combination was also associated with a rapid onset of analgesia, an important consideration for patients experiencing substantial pain during the early post-operative period. The findings support the concept that combining analgesics with complementary mechanisms may produce more effective pain control than relying on a single non-opioid medicine. Multimodal approaches are increasingly important in postoperative care as clinicians seek effective pain management strategies while minimizing unnecessary exposure to opioid medications.
Long-Lasting Relief Observed After Surgery
One of the key features highlighted by Kenvue was the duration of pain relief provided by the combination. Clinical evidence presented at the meeting demonstrated sustained analgesic activity following administration, potentially helping patients manage pain for longer periods between doses. The ability to provide prolonged relief can be particularly important during the first days following surgery, when pain may interfere with sleep, mobility, physical activity and recovery. Effective pain control can also support patients in participating in rehabilitation and returning to normal activities. The studies used validated measures of acute pain and pain intensity to evaluate treatment response. Researchers assessed the overall pain-relief profile of the combination over the post-dose observation period, providing evidence on both the magnitude and duration of analgesic effects. While the results are encouraging, the clinical evidence should be interpreted within the context of the specific surgical models and study populations evaluated. Individual responses to analgesics can vary depending on the type of surgery, baseline pain intensity, patient characteristics and other medications being used.
Advertisement
Non-Opioid Options Address Postoperative Pain Needs
The findings are relevant to the broader effort to expand non-opioid pain management options. Acute post-surgical pain is common, and inadequate pain control can affect recovery and quality of life. At the same time, healthcare providers continue to consider approaches that can reduce reliance on opioid analgesics when clinically appropriate. The combination of acetaminophen and naproxen provides a pharmacological strategy that brings together two widely used non-opioid analgesics. By targeting pain through complementary mechanisms, combination therapy may provide broader analgesic activity while potentially reducing the need for additional rescue medication in appropriate patients. Kenvue presented the new evidence at PAINWeek 2026, a major medical meeting focused on pain management and related clinical practice. The company said the findings add to its growing body of evidence supporting combination approaches for acute pain.
The results nevertheless do not mean the combination is appropriate for every patient. Naproxen and acetaminophen have established safety considerations, including gastrointestinal, cardiovascular, renal and liver-related risks under certain circumstances. Appropriate dosing and patient selection remain important when using these medicines. Overall, the PAINWeek findings strengthen the clinical evidence surrounding TYLENOL with Naproxen as a non-opioid approach to acute post-surgical pain and highlight the continued development of multimodal strategies aimed at delivering effective, sustained pain relief while limiting opioid exposure.
Source: Kenvue press release
